Unfolding narratives, shaping futures

We're always working to initiate change for patients

This section includes information and helpful resources so you can stay up to date on the latest UroGen innovations, events, news coverage, and more.

UroGen® profile

UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urological and specialty cancers because patients deserve better options. UroGen has developed a proprietary innovative technology platform, RTGel®, a reverse-thermal sustained-release hydrogel that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained-release technology is designed to work with the urologic anatomy—not against it—enabling longer exposure of the urinary tract tissue to medications and making local therapy a potentially more effective treatment option.

Jelmyto® (mitomycin) for pyelocalyceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade intermediate risk non-muscle invasive bladder cancer, are designed to ablate tumors by nonsurgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.

See our pipeline

Our leadership

See full leadership team

News releases

Jul 7, 2025

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

PRINCETON, N.J. , July 07, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has completed patient enrollment in its Phase 3 UTOPIA

Read story

Jun 12, 2025

U.S. FDA Approves UroGen’s ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

<p>ZUSDURI (formerly known as UGN-102) is a localized medication designed for potent tumor ablation delivered by innovative RTGel ® technology. Approval supported by pivotal Phase 3 ENVISION trial demonstrating 78% of patients achieved complete response (CR) at 3 months, and 79% of those responders</p>

Read story

Jun 6, 2025

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PRINCETON, N.J. --(BUSINESS WIRE)--Jun. 6, 2025-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 27 new

Read story

Events

Jun 13, 2025

UroGen Pharma ZUSDURI Approval Investor Call

Listen to webcast

May 28, 2025

TD Cowen: 6th Annual Oncology Innovation Summit: Insights for ASCO & EHA

Listen to webcast

May 12, 2025

UroGen Pharma Q1 2025 Earnings Call

Listen to webcast

Mar 10, 2025

UroGen Pharma Q4 2024 Earnings Call

Listen to webcast

Mar 3, 2025

TD Cowen 45th Annual Health Care Conference

Listen to webcast

Feb 20, 2025

Advancing Our Mission to Transform Cancer Care

Listen to webcast

Feb 11, 2025

Oppenheimer 35th Annual Healthcare Life Sciences Conference

Listen to webcast

Feb 5, 2025

Guggenheim Securities SMID Cap Biotech Conference

Listen to webcast

Nov 6, 2024

UroGen Pharma Q3 2024 Earnings Call

Listen to webcast

Sep 17, 2024

2024 Cantor Global Healthcare Conference

Listen to webcast
Connect with us
For more information about our products